Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
Authors
Keywords
-
Journal
CLINICAL PHARMACOKINETICS
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-02-13
DOI
10.1007/s40262-019-00742-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies
- (2018) Dongfen Yuan et al. AAPS Journal
- Eculizumab: A Review in Generalized Myasthenia Gravis
- (2018) Sohita Dhillon DRUGS
- The impact of eculizumab on routine complement assays
- (2018) Maria A.V. Willrich et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome
- (2018) Aysegul Oruc et al. NEFROLOGIA
- Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action
- (2018) Douglas Sheridan et al. PLoS One
- Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study
- (2018) Austin G. Kulasekararaj et al. BLOOD
- Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study
- (2018) Jong Wook Lee et al. BLOOD
- Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes
- (2017) Michela Sica et al. Journal of Hematology & Oncology
- Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study
- (2017) Amy I. Davidson et al. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
- Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
- (2017) Timothy H.J. Goodship et al. KIDNEY INTERNATIONAL
- Haemolytic uraemic syndrome
- (2017) Fadi Fakhouri et al. LANCET
- Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
- (2017) James F Howard et al. LANCET NEUROLOGY
- The renaissance of complement therapeutics
- (2017) Daniel Ricklin et al. Nature Reviews Nephrology
- Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab
- (2017) Ryan Gately et al. NEPHROLOGY
- Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome
- (2017) Kioa L Wijnsma et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update
- (2017) Gianluigi Ardissino et al. PEDIATRIC NEPHROLOGY
- Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence
- (2017) Savino Sciascia et al. RHEUMATOLOGY INTERNATIONAL
- Eculizumab for the treatment of hemolytic paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and refractory myasthenia gravis
- (2017) Jörg Schubert et al. Expert Opinion on Orphan Drugs
- Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria
- (2016) Peter Hillmen et al. AMERICAN JOURNAL OF HEMATOLOGY
- Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation
- (2016) Dror Mevorach et al. ANNALS OF NEUROLOGY
- Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation
- (2016) Sonata Jodele et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation
- (2016) Markus J. Harder et al. BLOOD
- Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders
- (2016) C. Wehling et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation
- (2016) Fadi Fakhouri et al. Clinical Journal of the American Society of Nephrology
- Off-label use of the expensive orphan drug eculizumab in France 2009–2013 and the impact of literature: focus on the transplantation field
- (2016) Johann Castañeda-Sanabria et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan
- (2016) Haruhiko Ninomiya et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Genetic variants ofC5and polymorphisms ofC3in Chinese patients with paroxysmal nocturnal hemoglobinuria
- (2016) Y. Du et al. International Journal of Laboratory Hematology
- Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway
- (2016) Janus Asbjørn Schatz-Jakobsen et al. JOURNAL OF IMMUNOLOGY
- Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment
- (2016) Johan Vande Walle et al. JOURNAL OF NEPHROLOGY
- Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
- (2016) Larry A. Greenbaum et al. KIDNEY INTERNATIONAL
- Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab
- (2016) Aude Servais et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey
- (2016) Fusun Gediz et al. TRANSFUSION AND APHERESIS SCIENCE
- Eculizumab for Treatment of Rapidly Progressive C3 Glomerulopathy
- (2015) Moglie Le Quintrec et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Discontinuation of Eculizumab Treatment in Atypical Hemolytic Uremic Syndrome: An Update
- (2015) Gianluigi Ardissino et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Management of pregnancy in paroxysmal nocturnal hemoglobinuria on long-term eculizumab
- (2015) Marie-Christiane Vekemans et al. BLOOD COAGULATION & FIBRINOLYSIS
- Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan
- (2015) Naoko Ito et al. Clinical and Experimental Nephrology
- Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome
- (2015) Elena B. Volokhina et al. CLINICAL IMMUNOLOGY
- Eculizumab in Pediatric Dense Deposit Disease
- (2015) M. J. S. Oosterveld et al. Clinical Journal of the American Society of Nephrology
- Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort
- (2015) A. Mallett et al. INTERNAL MEDICINE JOURNAL
- Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
- (2015) Christoph Licht et al. KIDNEY INTERNATIONAL
- Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule
- (2015) Philippe Gatault et al. mAbs
- Atypical aHUS: State of the art
- (2015) Carla M. Nester et al. MOLECULAR IMMUNOLOGY
- Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria
- (2015) Richard J. Kelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy
- (2015) Flore Sicre de Fontbrune et al. TRANSPLANTATION
- Eculizumab for Treatment of Refractory Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience
- (2015) B. Yelken et al. TRANSPLANTATION PROCEEDINGS
- Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab
- (2014) R. Peffault de Latour et al. BLOOD
- Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults
- (2014) S. Jodele et al. BLOOD
- Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment
- (2014) M. Cugno et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis
- (2014) C. Wehling et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Opportunity Cost of Funding Drugs for Rare Diseases
- (2014) Doug Coyle et al. MEDICAL DECISION MAKING
- Update on C3 glomerulopathy
- (2014) Thomas D. Barbour et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Genetic Variants in C5 and Poor Response to Eculizumab
- (2014) Jun-ichi Nishimura et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria
- (2014) Ulrike M. Reiss et al. PEDIATRIC BLOOD & CANCER
- Eculizumab hepatotoxicity in pediatric aHUS
- (2014) Wesley Hayes et al. PEDIATRIC NEPHROLOGY
- Hemolytic uremic syndrome
- (2014) Caterina Mele et al. Seminars in Immunopathology
- Eculizumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantation–Associated Thrombotic Microangiopathy
- (2013) Sonata Jodele et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
- (2013) Peter Hillmen et al. BRITISH JOURNAL OF HAEMATOLOGY
- Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study
- (2013) Sean J Pittock et al. LANCET NEUROLOGY
- A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis
- (2013) James F. Howard et al. MUSCLE & NERVE
- Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab
- (2013) Y. Delmas et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
- (2013) C.M. Legendre et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eculizumab for Atypical Hemolytic Uremic Syndrome in Pregnancy
- (2013) Gianluigi Ardissino et al. OBSTETRICS AND GYNECOLOGY
- Systemic Complement Inhibition with Eculizumab for Geographic Atrophy in Age-Related Macular Degeneration
- (2013) Zohar Yehoshua et al. OPHTHALMOLOGY
- Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis
- (2012) A. S. Bomback et al. Clinical Journal of the American Society of Nephrology
- Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
- (2012) Julien Zuber et al. Nature Reviews Nephrology
- Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic–uraemic syndrome: an analysis of the German STEC-HUS registry
- (2012) Jan T. Kielstein et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Eculizumab for the Treatment of Dense-Deposit Disease
- (2012) Marina Vivarelli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Terminal Complement Inhibition Decreases Antibody-Mediated Rejection in Sensitized Renal Transplant Recipients
- (2011) M. D. Stegall et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival
- (2011) R. J. Kelly et al. BLOOD
- Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena
- (2011) Alexander Röth et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- An open label clinical trial of complement inhibition in multifocal motor neuropathy
- (2011) Amanda M. Fitzpatrick et al. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
- Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria
- (2010) Peter Hillmen et al. AMERICAN JOURNAL OF HEMATOLOGY
- The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab
- (2010) Richard Kelly et al. BRITISH JOURNAL OF HAEMATOLOGY
- Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria
- (2010) Anita Hill et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Ron J. Keizer et al. CLINICAL PHARMACOKINETICS
- Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria
- (2008) Jrg Schubert et al. BRITISH JOURNAL OF HAEMATOLOGY
- FDA Report: Eculizumab (Soliris(R)) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
- (2008) A. Dmytrijuk et al. ONCOLOGIST
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More